8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Compare how the FDA and EMA regulate alendronate (Fosamax). Covers approval timelines, label language, post-market surveillance for atypical fractures and osteonecrosis, and what the differences mean for prescribers.
A clinical review of alendronate (Fosamax) safety signals reported through the FDA Adverse Event Reporting System (FAERS), including atypical femoral fractures, osteonecrosis of the jaw, and esophageal events.
A complete regulatory guide to alendronate (Fosamax) compounding legal status, FDA approval history, label requirements, and post-market safety data. Reviewed by the HealthRX medical team.
A complete, clinically accurate account of Fosamax (alendronate) FDA approval history, label changes, post-market safety updates, and what prescribers and patients need to know in 2025.
A complete guide to Fosamax (alendronate) regulatory history across the FDA, EMA, and major markets, including label changes, black-box warnings, and post-market safety findings.
A complete review of every FDA label update to Fosamax (alendronate) from 2020 through 2026, including new safety signals, dosing guidance, and post-market surveillance data reviewed by the HealthRX.com medical team.
A clinical review of alendronate (Fosamax) regulatory history, patent disputes, FDA label revisions, and major litigation outcomes including the landmark preemption case.
A clinical review of alendronate (Fosamax) FDA history, current label, post-market safety surveillance, and the next-generation osteoporosis pipeline including romosozumab, odanacatib, and sequential therapy strategies.